{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:25:20Z","timestamp":1765891520080,"version":"3.48.0"},"reference-count":38,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"crossref","award":["EMA\/2018\/23\/PE"],"award-info":[{"award-number":["EMA\/2018\/23\/PE"]}],"id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Policy and Practice"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/20523211.2025.2576620","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:16:31Z","timestamp":1762175791000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Perspectives on the impact of regulatory measures on national COVID-19 vaccination programs: a qualitative study from six EU member states"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6226-5491","authenticated-orcid":false,"given":"E.D.","family":"van Vliet","sequence":"first","affiliation":[{"name":"Centre for Health Protection, National Institute for Public Health and the Environment (RIVM)","place":["Bilthoven, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Buhl","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8142-9807","authenticated-orcid":false,"given":"R.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9713-4407","authenticated-orcid":false,"given":"A.","family":"Andersen","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.B.","family":"Almarsd\u00f3ttir","sequence":"additional","affiliation":[{"name":"University of Copenhagen","place":["Copenhagen, Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Dermiki-Gkana","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Oikonomou","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Deligianni","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7835-8246","authenticated-orcid":false,"given":"C.","family":"Kontogiorgis","sequence":"additional","affiliation":[{"name":"Democritus University of Thrace","place":["Alexandroupolis, Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kos","sequence":"additional","affiliation":[{"name":"University of Ljubljana","place":["Ljubljana, Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"\u010cebron Lipovec","sequence":"additional","affiliation":[{"name":"University of Ljubljana","place":["Ljubljana, Slovenia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8158","authenticated-orcid":false,"given":"I.","family":"Ribeiro-Vaz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of University of Porto","place":["Porto, Portugal"]},{"name":"Faculty of Medicine of University of Porto","place":["Porto, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Silva","sequence":"additional","affiliation":[{"name":"Faculty of Medicine of University of Porto","place":["Porto, Portugal"]},{"name":"Faculty of Medicine of University of Porto","place":["Porto, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5712-1338","authenticated-orcid":false,"given":"P.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy of University of Lisbon","place":["Lisbon, Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Poplavska","sequence":"additional","affiliation":[{"name":"Riga Stradins University","place":["Riga, Latvia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0482-5563","authenticated-orcid":false,"given":"S.","family":"Abtahi","sequence":"additional","affiliation":[{"name":"Utrecht University","place":["Utrecht, the Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Hegger","sequence":"additional","affiliation":[{"name":"Centre for Health Protection, National Institute for Public Health and the Environment (RIVM)","place":["Bilthoven, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Leonardo Alves","sequence":"additional","affiliation":[{"name":"Centre for Health Protection, National Institute for Public Health and the Environment (RIVM)","place":["Bilthoven, The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.12.065"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01405-9"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101616"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100192"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5084"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2828"},{"key":"e_1_3_3_8_1","volume-title":"Overview of EU\/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making","author":"European Centre for Disease Prevention and Control","year":"2021","unstructured":"European Centre for Disease Prevention and Control. (2021). Overview of EU\/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/overview-eueea-country-recommendations-covid-19-vaccination-vaxzevria-and-scoping."},{"key":"e_1_3_3_9_1","volume-title":"COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 6 October 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021a). COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 6 October 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-6-october-2021_en.pdf."},{"key":"e_1_3_3_10_1","volume-title":"COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 11 May 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021b). COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 11 May 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-11-may-2021_en.pdf."},{"key":"e_1_3_3_11_1","volume-title":"COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 14 April 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021c). COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 14 April 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-april-2021_en.pdf."},{"key":"e_1_3_3_12_1","volume-title":"COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 14 July 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021d). COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 14 July 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-14-july-2021_en.pdf."},{"key":"e_1_3_3_13_1","volume-title":"COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 18 June 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021e). COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 18 June 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-18-june-2021_en.pdf."},{"key":"e_1_3_3_14_1","volume-title":"COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 22 April 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021f). COVID-19 vaccine safety update COVID-19 VACCINE JANSSEN Janssen-Cilag International NV \u2013 22 April 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-covid-19-vaccine-janssen-22-april-2021_en.pdf."},{"key":"e_1_3_3_15_1","volume-title":"COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 8 September 2021 corr1","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021g). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 8 September 2021 corr1. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-8-september-2021_en.pdf."},{"key":"e_1_3_3_16_1","volume-title":"COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 11 May 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021h). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 11 May 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-11-may-2021_en.pdf."},{"key":"e_1_3_3_17_1","volume-title":"COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 14 April 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021i). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 14 April 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-april-2021_en.pdf."},{"key":"e_1_3_3_18_1","volume-title":"COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 14 July 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021j). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 14 July 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-14-july-2021_en.pdf."},{"key":"e_1_3_3_19_1","volume-title":"COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 18 June 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021k). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 18 June 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-18-june-2021_en.pdf."},{"key":"e_1_3_3_20_1","volume-title":"COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 21 May 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021l). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 21 May 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-21-may-2021_en.pdf."},{"key":"e_1_3_3_21_1","volume-title":"COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 29 march 2021","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021m). COVID-19 vaccine safety update VAXZEVRIA AstraZeneca AB \u2013 29 march 2021. https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccine-safety-update-vaxzevria-previously-covid-19-vaccine-astrazeneca-29-march-2021_en.pdf."},{"key":"e_1_3_3_22_1","volume-title":"DHPC \u2013 COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021n). DHPC \u2013 COVID-19 Vaccine AstraZeneca: Risk of thrombocytopenia and coagulation disorders. https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en.pdf."},{"key":"e_1_3_3_23_1","volume-title":"DHPC \u2013 COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021o). DHPC \u2013 COVID-19 Vaccine Janssen: Contraindication in individuals with previous capillary leak syndrome and update on thrombosis with thrombocytopenia syndrome. https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/covid-19-vaccine-janssen-contraindication-individuals-previous-capillary-leak-syndrome-update."},{"key":"e_1_3_3_24_1","volume-title":"DHPC \u2013 COVID-19 Vaccine Janssen: Link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021p). DHPC \u2013 COVID-19 Vaccine Janssen: Link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia. https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/covid-19-vaccine-janssen-link-between-vaccine-occurrence-thrombosis-combination-thrombocytopenia."},{"key":"e_1_3_3_25_1","volume-title":"DHPC \u2013 VAXZEVRIA\/COVID-19 Vaccine AstraZeneca: Link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021q). DHPC \u2013 VAXZEVRIA\/COVID-19 Vaccine AstraZeneca: Link between the vaccine and the occurrence of thrombosis in combination with thrombocytopenia. https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-vaxzevria-previously-covid-19-vaccine-astrazeneca_en-0.pdf."},{"key":"e_1_3_3_26_1","volume-title":"DHPC \u2013 VAXZEVRIA\/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with thrombocytopenia \u2013 Updated information","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021r). DHPC \u2013 VAXZEVRIA\/COVID-19 Vaccine AstraZeneca: Risk of thrombosis in combination with thrombocytopenia \u2013 Updated information. https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-vaxzevria\/covid-19-vaccine-astrazeneca-risk-thrombosis-combination-thrombocytopenia-updated-information_en.pdf."},{"key":"e_1_3_3_27_1","volume-title":"EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021s). EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome. https:\/\/www.ema.europa.eu\/en\/news\/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia."},{"key":"e_1_3_3_28_1","volume-title":"JCOVDEN \u2013 Procedural steps taken and scientific information after the authorisation","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021t). JCOVDEN \u2013 Procedural steps taken and scientific information after the authorisation. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/covid-19-vaccine-janssen-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf."},{"key":"e_1_3_3_29_1","volume-title":"Vaxzevria \u2013 Procedural steps taken and scientific information after the authorisation","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. (2021u). Vaxzevria \u2013 Procedural steps taken and scientific information after the authorisation. https:\/\/www.ema.europa.eu\/en\/documents\/procedural-steps-after\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-procedural-steps-taken-scientific-information_en.pdf."},{"key":"e_1_3_3_30_1","volume-title":"EPAR - Jcovden (previously COVID-19 Vaccine Janssen)","author":"European Medicines Agency","year":"2023","unstructured":"European Medicines Agency. (2023a). EPAR - Jcovden (previously COVID-19 Vaccine Janssen). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jcovden-previously-covid-19-vaccine-janssen."},{"key":"e_1_3_3_31_1","volume-title":"EPAR - Vaxzevria (previously COVID-19 Vaccine AstraZeneca)","author":"European Medicines Agency","year":"2023","unstructured":"European Medicines Agency. (2023b). EPAR - Vaxzevria (previously COVID-19 Vaccine AstraZeneca). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaxzevria."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-025-01537-6"},{"key":"e_1_3_3_34_1","volume-title":"Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines in context of thrombosis with thrombocytopenia syndrome (TTS): Risk awareness and adherence (RiskAwareTTS)","author":"HMA-EMA Catalogue of Real-World Data.","year":"2022","unstructured":"HMA-EMA Catalogue of Real-World Data. (2022). Impact of EU label changes and regulatory communication on SARS-CoV-2 adenovirus vector vaccines in context of thrombosis with thrombocytopenia syndrome (TTS): Risk awareness and adherence (RiskAwareTTS). European Medicines Agency. https:\/\/catalogues.ema.europa.eu\/node\/3434\/administrative-details."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109908"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1114"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.650525"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7517"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70057"}],"container-title":["Journal of Pharmaceutical Policy and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/20523211.2025.2576620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:21:15Z","timestamp":1765891275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/20523211.2025.2576620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/20523211.2025.2576620"],"URL":"https:\/\/doi.org\/10.1080\/20523211.2025.2576620","relation":{},"ISSN":["2052-3211"],"issn-type":[{"type":"electronic","value":"2052-3211"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=jppp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2576620"}}